The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing
population and introduction of screening for high-risk individuals. Optimal management …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

The treatment of stage III non–small-cell lung cancer has evolved over the last two decades,
with combined-modality therapy the current standard of care. As a result, intermediate and …

Despite cures in early stage (IA–IIB) non-small cell lung cancer (NSCLC), the 5-year survival
rate is only 36%–73%. Surgical resection via lobectomy is the treatment of choice in early …

The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma
(NSCLC) as consisting of patients with a T1 or T2 primary tumor designation and no …

Background The appropriate staging and treatment of patients with stage I and II non-small-
cell lung cancer (NSCLC) are important in that the potential for a lost curative opportunity in …

Background Stage IIIB non-small-cell lung cancer (NSCLC) is usually thought to be
unresectable, and is managed with chemotherapy with or without radiotherapy. However …

The most effective treatment for patients with early-stage non–small-cell lung cancer
(NSCLC) remains complete surgical resection, providing the disease is medically operable …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

In functionally fit patients with localized disease surgical resection remains the treatment of
choice. There is also good evidence to support the use of chemotherapy in stages II-III …